Softwr

Healthcare · head to head

PathAI vs Updox

PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-
Full reviewWebsite
Updox logo

Updox

Healthcare

Healthcare communications platform for eFax, telehealth and patient reminders

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.; Updox no specific dollar amounts listed on pricing page
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which PathAI and Updox actually diverge.

Attributes where PathAI and Updox differ
AttributePathAIUpdox

Identical on both: starting price (On request), pricing model (quote), free tier (No), platforms (Web), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

Only in Updox

Nothing recorded that PathAI does not also cover.

What people use each for

The jobs each tool is most often brought in to do.

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot Updox
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot Updox
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot Updox
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot Updox

Updox

  • Healthcare communication and patient engagementnot PathAI
  • Medical practice fax, telehealth, and SMS messagingnot PathAI
  • Charge capture and medical billing workflowsnot PathAI
  • Multi-location healthcare systemsnot PathAI

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

Updox

  • No specific dollar amounts listed on pricing page
  • Actual costs require contacting sales team or scheduling a demo
  • Standard and Enterprise tier limits shown but no pricing transparency

Pricing, plan by plan

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

Updox

On request

No published plan breakdown. See the Updox review.

Which should you pick?

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.
PathAI review

Choose Updox if

Nothing in the data separates Updox from PathAI on the points above - pick on price and on how each one feels to use.

Updox review

Questions people ask

Is PathAI or Updox better?
Neither clearly leads. PathAI starts at On request and Updox at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, PathAI or Updox?
PathAI starts at On request and Updox at On request.
Does PathAI or Updox run on more platforms?
Both run on Web, so platform support will not decide this one for you.
What is PathAI best used for?
PathAI is most often used for an academic medical centre going digital for primary diagnosis that needs the fda cleared aisight dx configuration rather than the research labelled version, a reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any location, a pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readers, a laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewer. Of those, an academic medical centre going digital for primary diagnosis that needs the fda cleared aisight dx configuration rather than the research labelled version and a reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any location are not what Updox is typically brought in for.
What can PathAI do that Updox cannot?
PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management.

Answered from the vendors’ own pages

PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

Updox: How much does Updox cost?

Updox pricing is not published on the pricing page. The vendor offers customizable packages and directs inquiries to schedule a demo or contact the sales team for personalized pricing based on practice size and tool requirements.

Source
PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

Updox: What is Updox's pricing model?

Updox uses a usage-based pricing model with customizable packages. Costs are tailored based on the tools selected (fax pages, telehealth sessions, patient reminders, text messages, broadcast messages) and can scale with practice benchmark data.

Source
PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

Updox: What limits are included in Updox's Standard tier?

Updox Standard tier includes up to 1,000 fax pages, 75 telehealth sessions, reminders for 500 appointments, 500 text messages, and 500 broadcast messages monthly, with higher limits available in Enterprise tier.

Source
PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Share

Related pages

More on PathAI

More on Updox

Keep looking

Other head to heads